KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Outstanding (Weighted Average) (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $209.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 1.55% year-over-year to $209.9 million, compared with a TTM value of $209.9 million through Dec 2025, up 1.55%, and an annual FY2025 reading of $209.9 million, up 1.55% over the prior year.
  • Shares Outstanding (Weighted Average) was $209.9 million for Q4 2025 at Biocryst Pharmaceuticals, roughly flat from $209.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $209.9 million in Q4 2025 and bottomed at $192.2 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $206.2 million, with a median of $206.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 7.54% in 2024, then increased 1.27% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $192.2 million in 2023, then rose by 7.54% to $206.7 million in 2024, then grew by 1.55% to $209.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BCRX at $209.9 million in Q4 2025, $209.5 million in Q3 2025, and $209.2 million in Q2 2025.